AMGNAmgen Inc.
# 13 · $439.26 (-1.79%) · $237.48B · Healthcare
52-week range
High-severity risk signals
The scoring engine flagged these high-severity signals. They are warnings to investigate and are not part of the score.
- Altman Z in distress zone
Market data
- P/E
- 27.28
- 1M
- +8.18%
- 1Y
- +54.13%
- Yield
- 2.26%
- RSI
- 69.46
- MACD
- +0.63%
Breakdown
Why
- PEG of 0.31
- earnings growth of 88.5%
- revenue growth of 10.0%
- ROE of 74.8%
- profit margin of 23.0%
- margin and ROA expanding YoY
- 12-1 momentum return of 42.5%
- trading 19.2% above 200d SMA
- MACD histogram positive
- EPS vs. estimates: +11.1% on average
Rationale is generated by the scoring engine (English).
Piotroski F-Score
7
7 / 9 checks passed
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Risk signals
- Altman Z in distress zoneHigh
Z-Score 0.56 (< 1.81) — financial distress risk per the Altman model
- High leverageMedium
debt/equity 490% (alert threshold 200%)
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Geographic revenue concentrationInfo
72% of revenue from United States
- Product revenue concentrationInfo
96% of revenue from Products
Company research
Business Overview Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes prescription biologic medicines and other therapies, generating revenue primarily from product sales to wholesalers/distributors, hospitals, and specialty pharmacies. Key marketed products include Enbrel, Prolia/XGEVA (denosumab), Repatha (evolocumab), TEZSPIRE (tezepelumab), BLINCYTO, and KYPROLIS. Market Position Amgen is one of the largest global biotech companies with a diversified portfolio across inflammation, oncology/hematology, bone health, and cardiovascular, and it competes through scale in biologics manufacturing, broad commercial reach, and lifecycle management (including biosimilars). Competitive dynamics are heavily influenced by patent/LOE timing and biosimilar/brand competition in major franchises. Key Segments Amgen reports as one operating segment, managing the business on a consolidated basis rather than distinct reportable segments.
AI-generated summary based on third-party data; it may contain errors. Not investment advice or a recommendation to invest.
Period: 2021-12-31 → 2025-12-31